Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AQST vs AYTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AYTU Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–4 Matrix Metrics)

AYTU Overall Winner 6-Pillar Tally: AQST 0 – 6 AYTU Matrix Metrics: AQST 4 – 6 AYTU

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQST carries a Unified Composite Score of 59.4/100 (HOLD) at $3.77 (N/M Forward P/E, -114.1% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin).

  • Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (59.4/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -114.1% operating margin) and revenue trajectory (+6.4% vs. -41.0% YoY).
  • Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.9); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AQST vs AYTU
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.77
-3.45% 1D
Market Cap $448.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.87β · 56% Vol
Unified Composite Score
59.4 / 100 HOLD
Tech 69.0 Fund 66.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 44
RSI-14: 43.9 · SMA20: $3.85 · SMA50: $4.34
AYTU NASDAQ Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00

6-Pillar Scorecard Institutional Category Breakdown (AQST 0 – 6 AYTU)

Columns: Metric · AQST · AYTU
1. Valuation Multiples AYTU
Forward P/E N/M 9.2x
Trailing P/E N/M 9.2x
PEG Ratio N/M N/M
EV / Revenue 8.5x 0.3x
2. Growth & Scale AYTU
Revenue Growth (YoY) -41.0% +6.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $49M $58M
Market Cap $448.7M $19.6M
3. Profitability & Quality AYTU
Gross Margin 65.3% 64.0%
Operating Margin -114.1% -14.4%
Net Profit Margin -162.3% -24.8%
Return on Equity (ROE) 0.0% -52.5%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$41M -$1.4M
Cash Flow Margin -83.3% -2.4%
Net Cash / Leverage $32M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AYTU
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 61.9% (40th %ile) N/A (N/A)
Put/Call OI Skew 0.38x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity N/A 78.4% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AQST (4) vs AYTU (6)
Institutional Metric AQST AYTU Criterion Row Edge
Market Capitalization
Scale
$448.7M $19.6M Larger Scale AQST
Trailing P/E Ratio
Valuation
N/M 9.2x Lower Multiple AYTU
Forward P/E Ratio
Valuation
N/M 9.2x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
-41.0% +6.4% Higher Growth AYTU
Operating Margin (TTM)
Profitability
-114.1% -14.4% Higher Margin AYTU
Net Profit Margin
Profitability
-162.3% -24.8% Higher Margin AYTU
Return on Equity (ROE)
Capital Efficiency
0.0% -52.5% Higher ROE AQST
52-Week Range Position
Momentum
22% ($3–$7) 5% ($2–$3) Stronger Trend AQST
Beta / 30D Volatility
Risk Regime
0.87β · 56% Vol 0.65β · 35% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
59.4 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$49M $58M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.3% 64.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.5x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$41M ($32M Net Cash) -$1.4M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AQST +11.14 pp
AQST: -0.13% · AYTU: -11.27%
3M Horizon AQST +10.69 pp
AQST: -12.62% · AYTU: -23.31%
6M Horizon AQST +5.1 pp
AQST: -8.71% · AYTU: -13.81%
1Y Horizon AYTU +16.63 pp
AQST: -28.77% · AYTU: -12.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AQST Revenue AYTU Revenue AQST Op. Margin AYTU Op. Margin Margin Leader
FY2019 $50M $10M -100.1% -230.1% AQST
FY2020 $50M $30M -93.6% -76.5% AYTU
FY2021 $50M $70M -68.2% -89.7% AQST
FY2022 $50M $100M -88.2% -113.7% AQST
FY2023 $50M $110M -29.9% -15.9% AYTU
FY2024 $60M $70M -53.5% -2.4% AYTU
FY2025 $40M $70M -159.5% -11.8% AYTU
FY2026 N/A $60M N/A -14.4% AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AQST BREAKDOWN
57d in phase · OBV DISTRIBUTION
Current IV 61.9%
IV Percentile 40th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $448.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ AQST vs AYTU Key Questions & Quantitative Answers

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQST carries a Unified Composite Score of 59.4/100 (HOLD) at $3.77 (N/M Forward P/E, -114.1% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin). Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (59.4/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -114.1% operating margin) and revenue trajectory (+6.4% vs. -41.0% YoY). Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.9); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AYTU leads the Growth & Scale pillar: AQST posts -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin), compared with AYTU at +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AQST cumulative revenue shifted -20.0% while AYTU shifted +500.0%. In operating R&D and SG&A reinvestment, AQST deploys N/A (0 90-day corporate R&D disclosures) versus 78.4% of Rev ($45M) (0 disclosures) for AYTU.

AYTU screens cheaper on headline valuation multiples. AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.5x EV/Revenue (-83.3% FCF margin), whereas AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQST (0.0% ROE) versus AYTU (-52.5% ROE) capital efficiency.

In options market volatility and institutional positioning, AQST carries 61.9% implied volatility (40th %ile, Balanced (25th–60th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.87β · 56% Vol realized risk). By comparison, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.